Inactive Instrument

Codiak BioSciences

CDAK

US1920101060

Codiak BioSciences, Inc. Announces Resignation of Ajay Verma as Executive Vice President, Research and Experimental Medicine

March 08, 2021 at 10:19 pm

On March 5, 2021, Ajay Verma, M.D., Ph.D., the Executive Vice President, Research and Experimental Medicine of Codiak BioSciences, Inc., separated from the company, effective as of March 5, 2021.

Latest news about Codiak BioSciences

Codiak BioSciences, Inc. Bankruptcy Case Dismissed	28/06/23	CI
Motion for Asset Sale Approved for Codiak BioSciences, Inc.	06/06/23	CI
Motion for Case Dismissal Filed by Codiak BioSciences, Inc.	06/06/23	CI
Motion for Asset Sale Approved for Codiak BioSciences, Inc.	06/06/23	CI
Bidding Procedure Approved for Codiak BioSciences, Inc.	27/04/23	CI
Interim Motion for Asset Sale Approved for Codiak BioSciences, Inc.	12/04/23	CI
Motion for Asset Sale Filed by Codiak BioSciences, Inc.	07/04/23	CI
Motion for Asset Sale Filed by Codiak BioSciences, Inc.	07/04/23	CI
Codiak BioSciences, Inc.(OTCPK:CDAK.Q) dropped from NASDAQ Composite Index	04/04/23	CI
Codiak BioSciences, Inc.(NasdaqGM:CDAK) dropped from S&P TMI Index	30/03/23	CI
North American Morning Briefing : Investor Mood -3-	29/03/23	DJ
Motion for Joint Administration Approved for Codiak BioSciences, Inc.	29/03/23	CI
Motion for Joint Administration Filed by Codiak BioSciences, Inc.	28/03/23	CI
Indian Morning Briefing : Asian Markets Rise as Banking Fears Ease	28/03/23	DJ
Health Care Lags Market as Novartis Rises -- Health Care Roundup	27/03/23	DJ
Sector Update: Health Care Stocks Rise in Late Trading	27/03/23	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	27/03/23	MT
Codiak BioSciences Files for Chapter 11 Bankruptcy, Plans to Sell Assets; Shares Plunge	27/03/23	MT
Codiak BioSciences, Inc. Filed for Bankruptcy	27/03/23	CI
Codiak BioSciences, Inc.(NasdaqGM:CDAK) dropped from NASDAQ Biotechnology Index	16/12/22	CI
Certain Restricted Stock Units of Codiak BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 12-DEC-2022.	11/12/22	CI
Certain Stock Options of Codiak BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 12-DEC-2022.	11/12/22	CI
Certain Common Stock of Codiak BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 12-DEC-2022.	11/12/22	CI
Goldman Sachs Adjusts Price Target on Codiak BioSciences to $1.40 From $2, Maintains Neutral Rating	07/11/22	MT
Codiak BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22	CI

Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx exosomes), focused on treating a range of diseases, including oncology, rare disease and infectious disease. Its product candidates include exoSTING, exoIL-12 and exoASO-STAT6. exoSTING is an exosome therapeutic candidate engineered with its engEx Platform to incorporate its stimulator of interferon genes (STING) agonist inside the lumen of the exosome. exoIL-12 is an exosome therapeutic candidate engineered using its engEx Platform to display IL-12 in a fully active form on the surface via its scaffold protein, prostaglandin F2 receptor negative regulator (PTGRFN).

Sector

More about the company